- Home
- PEPG vs ANTX Comparison
PEPG vs ANTX Comparison
Compare PEPG & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PEPG | ANTX |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.4M | 172.9M |
| IPO Year | 2022 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PEPG | ANTX |
|---|---|---|
| Price | $2.51 | $3.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $10.19 | $9.00 |
| AVG Volume (30 Days) | ★ 936.2K | 295.2K |
| Earning Date | 11-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.61 | ★ 32.56 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.31 | $1.00 |
| 52 Week High | $7.80 | $7.19 |
Technical Indicators
Market Signals| Indicator | PEPG | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.94 | 29.98 |
| Support Level | $2.24 | $2.87 |
| Resistance Level | $2.62 | $5.15 |
| Average True Range (ATR) | 0.23 | 0.33 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 32.20 | 14.64 |
Price Performance
Historical ComparisonAbout PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.